Showing results (471-480 of 526) with videos related to
Sort By:
Pageof 53
Blood|October 29, 2005
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cellsWeihua Wan, Mark S Albom, Lihui Lu, et al.Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.Bone Marrow Transplantation|July 3, 2014
Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationL Tucunduva, A Ruggeri, G Sanz, et al.Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.Leukemia|April 18, 2015
Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemiaA Ruggeri, M Labopin, G Sanz, et al.British Journal of Cancer|March 25, 2021
Detection of clustered circulating tumour cells in early breast cancerIlona Krol, Fabienne D Schwab, Roberta Carbone, et al.Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.Journal of Medicinal Chemistry|May 19, 2012
A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779Benjamin J Dugan, Diane E Gingrich, Eugen F Mesaros, et al.Bone Marrow Transplantation|August 20, 2013
Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysisR Cunha, P Loiseau, A Ruggeri, et al.Journal of Medicinal Chemistry|August 17, 2016
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)Gregory R Ott, Mangeng Cheng, Keith S Learn, et al.Pageof 53